SHELTON, Conn., Jan. 2, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE AMER: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, today announced it will be featured as a presenting company at the Biotech ShowcaseTM Investor Conference. The conference is being held on January 7-9, 2019 at the Hilton Union Square Hotel in San Francisco, CA.
Irach B. Taraporewala, Ph.D., CEO of NanoViricides, Inc., will provide an overview of the Company's business and recent progress in moving the company drug pipeline forward towards an Investigational New Drug (IND) Application during the presentation. He will be available to participate in one-on-one meetings with a number of investors who are registered to attend this conference and also interested parties attending the JP Morgan Conference being concomitantly held in San Francisco.
Event: Biotech ShowcaseTM Investor Conference Presentation Date: Monday, January 7, 2019 Presentation Time: 9:30 AM PST Location: Hilton Union Square Hotel, San Francisco, CA Yosemite C Room (Ballroom Level)
The Biotech ShowcaseTM Conference hosts presentations by over 400 biotechnology and pharmaceutical companies in the microcap and mid-cap range and attracts a wide investor base.
About NanoViricides NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including VZV, HSV-1, HSV-2., H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Dengue fever, and Ebola virus, among others. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
FDA refers to US Food and Drug Administration. EMA refers to the European Union's office of European Medical Agency.